nivolumab,etigilimab
mereo biopharmaceuticalceutical,bms,marker therapeutics
['nivo', 'etigilimab', 'solid tumor', 'biomarker', 'nivolumab', 'marker ', 'mereo ', '$mreo']
$mreo mereo biopharma reports clinical update and interim biomarker analysis presented at esmo 2022 from activate phase 1b/2 open label study of etigilimab (anti-tigit antibody mph-313) plus nivolumab (anti-pd-1 antibody) in solid tumors 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities